Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib

NCT01765543 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01765543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01765543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2013
Completion date
November 30, 2015
Enrollment
27 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, neoplasms